Sodium Butyrate: An Overlooked Supplement for Crohn's Disease

Sodium butyrate is a short chain fatty acid made by gut microbes and the main energy source for the cells lining the colon. Whether it helps in Crohn's disease is genuinely unsettled, and the best designed trial so far did not find a benefit. It is sold in the United States as a dietary supplement, which means it is regulated, but under a framework where nobody has to prove it works, or that it is safe, before it goes on sale. It is not regulated as a medication.

Crohn's disease is an immune-mediated inflammatory bowel disease whose underlying cause is not yet known. The current understanding is a dysregulated immune response to an altered gut microbiota in a genetically susceptible person, rather than a classic autoimmune attack on a single target. Unlike the other main form of inflammatory bowel disease, Crohn's disease can affect any part of the gastrointestinal system, from the mouth to the anus. Symptoms can include abdominal pain, fevers, diarrhea, and rectal bleeding. Over time complications can include scarring and strictures, nutritional deficiencies, abscesses, fistulas and bowel obstructions.

A 2005 study by Di Sabatino and colleagues gave enteric coated sodium butyrate to a group of Crohn's patients for 8 weeks. Nine of the thirteen responded and seven reached remission, and those who responded also had lower mucosal levels of the inflammatory markers NF-κB and IL-1β afterwards.

Three things about that study matter as much as its result. It had thirteen patients, no placebo group and no blinding, so there was nothing to measure the response against. In modern Crohn's trials somewhere between a fifth and a third of patients reach remission on placebo alone, which means a 69 percent response rate in thirteen unblinded patients is consistent with a modest benefit and equally consistent with none. And the dose was 4 grams a day, roughly 7 to 27 times what commercial capsules contain.

Since then the best designed trial has reported, and it was negative. Pietrzak and colleagues in 2022 ran a randomized, double blind, placebo controlled, multicenter trial in 72 children and adolescents with newly diagnosed inflammatory bowel disease, 42 of them with Crohn's, at 300 milligrams a day for 12 weeks. Remission was 62 percent on butyrate against 72 percent on placebo, a gap well within chance, and calprotectin, a marker of intestinal inflammation, did not separate either. The authors concluded that supplementation as adjunctive therapy did not show efficacy.

Two details make that result harder to explain away rather than easier. The trial gave butyrate on top of standard treatment, which is the way a supplement is actually used, so it was testing the realistic question rather than butyrate as a replacement. And it enrolled colonic disease specifically, which is where the mechanism should look best, since butyrate is fuel for colon cells and is produced by fermentation in the colon. It was tested on favorable ground, in its realistic role, and it did not separate from placebo. No adequately powered trial of oral butyrate in adult Crohn's disease has ever been done, so thirteen years on the evidence is weaker than this post once implied rather than stronger.

The proposed mechanism runs like this. Sodium butyrate down-regulates inflammatory cytokines, which would reduce the mucosal inflammation that drives Crohn's disease, and because it is an energy source for the cells lining the colon it is also thought to help that lining repair itself after injury. That is a coherent story, and coherent stories are exactly what controlled trials exist to check.

There is a mechanism pointing the other way, and it deserves airtime. A 2016 paper in Cell showed that butyrate suppresses the proliferation of intestinal stem cells at the concentrations normally found in the gut, and that the architecture of the colonic crypt appears to exist partly to keep butyrate away from those stem cells. When mucosal injury breaches that barrier, which is what an ulcer is, more butyrate may slow wound repair rather than speed it. Inflamed tissue may also be less able to burn butyrate for fuel in the first place. So the assumption that more butyrate must help a damaged colon heal is not a safe one.

The most consequential change since this post was written has nothing to do with butyrate. Crohn's treatment moved a long way between 2013 and now, with several new classes of biologic and small molecule therapy, and the target moved with it. The goal is no longer only that a patient feels better but that the bowel lining objectively heals. For moderate to severe disease, the American Gastroenterological Association's 2025 living guideline suggests starting advanced therapy rather than working up through older drugs step by step. Worth saying plainly: that is a conditional recommendation resting on very low certainty evidence, it applies to moderate to severe disease rather than mild, and several head to head and combination trials in this area missed their primary endpoints. The direction is still clear enough to change what a page about a supplement owes its reader.

So where does sodium butyrate sit in this practice? Not as a treatment for Crohn's disease. Conventional, guideline based therapy is the treatment, and butyrate is not a substitute for any part of it.

We do use it occasionally, as a nutritional addition rather than a therapy, in selected patients where there is reason to think their own short chain fatty acid production is low. That is a clinical judgment and worth naming as one. There is no standardized, validated clinical test for butyrate deficiency, so this is not a number anyone is treating toward a target. It is a selective addition layered on top of proper therapy, chosen in full knowledge of the negative trial rather than in ignorance of it, and it is never a reason to delay, reduce or replace anything else.

One practical note about the products themselves. No published analytical study has verified that any commercial butyrate supplement contains what its label claims. That is not an accusation aimed at any particular brand. It is a gap in what is known, and it is worth knowing the gap is there.

We do find structured self-tracking useful, and the technology for it has improved. One caution belongs alongside it. Symptoms in Crohn's disease track poorly with what is actually happening to the bowel lining, which is precisely why the field moved its long term target to objective healing. Someone can feel better while still ulcerating, and that damage accumulates and does not fully reverse. Informal tracking is also not the same thing as a true single patient trial, which requires randomization, blinding, washout periods and repeated crossovers. So tracking is worth doing alongside objective monitoring rather than instead of it.

Please contact us if you would like more information on the ways we help patients with inflammatory bowel disease in our practice in San Francisco. And please talk to your treating physician before adding any dietary supplement to your regimen, particularly while your Crohn's disease is active.